Gapping up
In reaction to strong earnings/guidance: KORS +14.7%, FN +9.8%, MAT+6.5%, PVH +6.5%, (PVH sees FY16 EPS above consensus; PVH unit Tommy Hilfiger Licensing and G-III (GIII) enter into a multi-year license agreement ), MNK +6.2%, LMNX +6%, GOOG +5.4%, CACC +3.1%, HW+3.1%, UPS +2.9%, APC +2.7%, (also said in its earnings release that it anticipates recommending to its Board an initial 2016 budget of ~$2.8 bln, which would be nearly 50% lower than 2015 ), DOW +2.7%, KMDA+2.4%, APU +1.2%, BAX +0.8%, NEU +0.6%, AGCO +0.5%
M&A news: LOJN +20.9% (CalAmp to acquire LoJack for $6.45/share; expected to be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months), SYT +5.4% (Bloomberg headline that ChemChina is near a deal to acquire Syngenta for ~$43 bln), FEYE +1.2% (acquires Invotas International)
Other news: ASTI +4% (cont strength), DD +2.3% (in symp with SYT), DOW+2.2% (in symp with SYT), CHRS +1.8% (CHS-1701, a proposed biosimilar of Neulasta (pegfilgrastim), met both primary endpoints), EVH +1.6% (forms new strategic alliance with Passport Health Plan, acquires certain assets and capabilities), CAMP +1.5% (CalAmp to acquire LoJack for $6.45/share; expected to be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months), M +1.4% (likely in symp with KORS), COH +0.8% (likely in symp with KORS)
Analyst comments: FIT +2.9% (Fitbit initiated with Outperform at Oppenheimer), NFLX +1.6% (upgraded to Overweight from Neutral at Piper Jaffray), KITE +0.5% (Kite Pharma initiated with Outperform at RBC Capital Mkts)
In reaction to strong earnings/guidance: KORS +14.7%, FN +9.8%, MAT+6.5%, PVH +6.5%, (PVH sees FY16 EPS above consensus; PVH unit Tommy Hilfiger Licensing and G-III (GIII) enter into a multi-year license agreement ), MNK +6.2%, LMNX +6%, GOOG +5.4%, CACC +3.1%, HW+3.1%, UPS +2.9%, APC +2.7%, (also said in its earnings release that it anticipates recommending to its Board an initial 2016 budget of ~$2.8 bln, which would be nearly 50% lower than 2015 ), DOW +2.7%, KMDA+2.4%, APU +1.2%, BAX +0.8%, NEU +0.6%, AGCO +0.5%
M&A news: LOJN +20.9% (CalAmp to acquire LoJack for $6.45/share; expected to be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months), SYT +5.4% (Bloomberg headline that ChemChina is near a deal to acquire Syngenta for ~$43 bln), FEYE +1.2% (acquires Invotas International)
Other news: ASTI +4% (cont strength), DD +2.3% (in symp with SYT), DOW+2.2% (in symp with SYT), CHRS +1.8% (CHS-1701, a proposed biosimilar of Neulasta (pegfilgrastim), met both primary endpoints), EVH +1.6% (forms new strategic alliance with Passport Health Plan, acquires certain assets and capabilities), CAMP +1.5% (CalAmp to acquire LoJack for $6.45/share; expected to be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months), M +1.4% (likely in symp with KORS), COH +0.8% (likely in symp with KORS)
Analyst comments: FIT +2.9% (Fitbit initiated with Outperform at Oppenheimer), NFLX +1.6% (upgraded to Overweight from Neutral at Piper Jaffray), KITE +0.5% (Kite Pharma initiated with Outperform at RBC Capital Mkts)